N-acetyl transferase 2 polymorphisms associated with isoniazid pharmacodynamics: Molecular features for ligand interaction

Anticancer Research

Volumn 30, Issue 8, 2010, Pages 3177-3180

  Ohkura, Kazuto ^a   Fukino, Katsumi ^a   Shinohara, Yasuo ^b   Hori, Hitoshi ^b  

^a CHIBA INSTITUTE OF SCIENCE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antituberculosis; Isoniazid; N acetyl transferase 2

Indexed keywords

ACETOHYDRAZIDE; ACETYLISONIAZID; ACYLTRANSFERASE; ARGININE; ARYLAMINE ACETYLTRANSFERASE; COENZYME A; HYDRAZINE; ISOLEUCINE; ISONIAZID; N ACYLTRANSFERASE 4; N ACYLTRANSFERASE 5; N ACYLTRANSFERASE 6; N ACYLTRANSFERASE 7; UNCLASSIFIED DRUG; LIGAND; NAT2 PROTEIN, HUMAN; TUBERCULOSTATIC AGENT;

AMINO ACID SEQUENCE; ARTICLE; DNA POLYMORPHISM; DRUG ACCUMULATION; DRUG BLOOD LEVEL; ELECTRIC POTENTIAL; ENZYME STRUCTURE; GENOTYPE; HUMAN; LIGAND BINDING; MOLECULAR MODEL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TUBERCULOSIS; CHEMICAL STRUCTURE; CHEMISTRY; GENETIC POLYMORPHISM; GENETICS; MOLECULAR GENETICS; STATIC ELECTRICITY;

AMINO ACID SEQUENCE; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; GENOTYPE; HUMANS; ISONIAZID; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; STATIC ELECTRICITY;

EID: 77957364718     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Butcher NJ, Boukouvala S, Sim E and Minchin RF: Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2: 30-42, 2002.
2. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR and van Jaarsveld PP: Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155: 1717-1722, 1997. (Pubitemid 27216683)
3. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T and Azuma J: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4: 256-261, 2002.
4. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY and Lee SD: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug induced hepatitis. Hepatology 35: 883-889, 2002.
5. Shimizu Y, Dobashi K, Mita Y, Endou K, Moriya S, Osano K, Koike Y, Higuchi S, Yabe S, Utsugi M, Ishizuka T, Hisada T, Nakazawa T and Mori M: DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb) 86: 374-381, 2006.
6. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA and Dunlap NE: Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113: 1178-1183, 1998.
7. Weiner M, Burman W, Vernon A, Benator D, Peloquin CA, Khan A, Weis S, King B, Shah N and Hodge T: Low isoniazid concentrations and outcome of tuberculosis treatment with once weekly isoniazid and rifapentine. Am J Respir Crit Care Med 167: 1341-1347, 2003.
8. Ozawa S, Katoh T, Inatomi H, Imai H, Kuroda Y, Ichiba M and Ohno Y: Association of genotypes of carcinogen-activating enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and aryl-amine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Int J Cancer 102: 418-421, 2002.
9. World Health Organization (2003) Standardized treatment regimen. In: Treatment of Tuberculosis: Guidelines for National Programmes. WHO/CDS/TB/2003.313. Geneva, WHO, 37-38, 2003.
10. Donald P R, Parkin D P, Seifart H I, Schaaf H S, van Helden P D, Werely C J, Sirgel F A, Venter A and Maritz J S: The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 63: 633-639, 2007.
11. Kubota R, Ohno M, Hasunuma T, Iijima H and Azuma J: Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol 63: 927-933, 2007. (Pubitemid 47387905)
12. Ohkura K, Nagamune H and Kourai H: Structural analysis of human-specific cytolysin intermedilysin aiming application to cancer immunotherapy. Anticancer Res 24: 3343-3354, 2004.
13. Ohkura K, Nagasawa H, Uto Y, Okamura N, Murakami A and Hori H: The role of Gc protein oligosaccharide structure: a risk-factor for COPD. Anticancer Res 26: 4073-4078, 2006.
14. Ohkura K, Sukeno A, Yamamoto K, Nagamune H, Maeda T and Kourai H: Analysis of structural features of bis-quaternary ammonium antimicrobial agents 4,4′-(α,ω)-polymethylene-dithio)bis(1-alkylpyridinium iodide)s using computational simulation. Bioorg Med Chem 11: 5035-5043, 2003.
15. Ohkura K and Hori H: Analysis of structure-permeability correlation of nitrophenol analogues in newborn rat abdominal skin using semiempirical molecular orbital calculation. Bioorg Med Chem 7: 309-314, 1999. (Pubitemid 29117093)
16. Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F and Ueno K: Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and glutathione-S- transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33: 187-195, 2008.